Canadian Medical and Surgical Knowledge Translation Research Group
12
2
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
33%
4 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Lipoprotein (a) and Vascular Regenerative Cell Content
Role: lead
Circulating Vascular Regenerative Cell Exhaustion in Individuals Without Type 2 Diabetes Who Are of South Asian or European Origins
Role: lead
Vascular Regenerative Cell Exhaustion in Adults with Peripheral Artery Disease (PAD-VRCE)
Role: lead
The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk
Role: lead
Functional Investigation of Endothelial Function and Regenerative Cell Exhaustion
Role: lead
Semaglutide and Vascular Regeneration
Role: lead
Generalizability of REDUCE-IT Results to People of South Asian Descent With Atherosclerotic Cardiovascular Disease in Canada (REDUCE-IT Canada SA)
Role: lead
Empagliflozin and Cardiac Remodelling in People Without Diabetes
Role: collaborator
The Role of South Asian vs European Origins on Circulating Regenerative Cell Exhaustion
Role: lead
Pro-vascular Regenerative Cell Exhaustion in Women With Polycystic Ovarian Syndrome
Role: lead
A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy
Role: lead
An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19
Role: lead
All 12 trials loaded